Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2314-7253
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies ; volume:8 ; number:1 ; day:26 ; month:3 ; year:2022 ; pages:1-11 ; date:12.2022
Future Journal of Pharmaceutical Sciences ; 8, Heft 1 (26.3.2022), 1-11, 12.2022
- Urheber
-
Iheanacho, Chinonyerem O.
Eze, Uchenna I. H.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s43094-022-00409-5
- URN
-
urn:nbn:de:101:1-2022061723233796607123
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Iheanacho, Chinonyerem O.
- Eze, Uchenna I. H.
- SpringerLink (Online service)
Ähnliche Objekte (12)
A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
COVID-19 Impfpflichtgesetz : mit der COVID-19-Impfpflichtverordnung (COVID-19-IV)
First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
COVID-19
COVID-19
Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex
A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
COVID-19 Impfpflichtgesetz : mit der COVID-19-Impfpflichtverordnung (COVID-19-IV)
First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
COVID-19
COVID-19
Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex
A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
COVID-19 Impfpflichtgesetz : mit der COVID-19-Impfpflichtverordnung (COVID-19-IV)
First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
COVID-19
COVID-19